Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Kids who need hormone-blocking drugs to prevent premature puberty — or delay it if they're trans — have lost a more affordable option. The remaining nearly identical drug costs eight times more. -
Kids who need a hormone-blocking drug to prevent premature puberty have lost an off-label option. The company that makes the medicine, which is 1/8 the cost of the FDA-approved version, withdrew it.
-
Using the COVID vaccine "off-label" — whether that's for booster shots or young children — may be tempting to some vaccine providers, but the CDC warns it could get them into trouble. -
Immediately after the Food and Drug Administration authorized Pfizer's vaccine, the company delivered fewer doses than its government contract projected. Federal officials say they didn't know why. -
If all goes to plan, Americans who got Pfizer or Moderna shots can get a third dose eight months after their last jab. Here's why health officials think you'll need one. -
NewsHouse subcommittee members questioned why Emergent BioSoultions awarded bonuses to executives despite quality problems than hindered production of Johnson & Johnson's COVID-19 vaccine. -
President Biden threw his support behind a World Trade Organization proposal that would waive intellectual property protections for COVID-19 vaccines — allowing countries to make their own vaccines.
-
NewsA dip of 86% in doses to be distributed to states follows a surge that occurred after one of J&J's third party manufacturers was finally able to release a stockpile. -
Johnson & Johnson has struggled with serious supply problems. Next week, states will have 86% fewer of the doses to dole out than they did this week.
-
The COVID-19 vaccine by Johnson and Johnson has hit a snag. One the facilities making a key ingredient didn't pass quality inspection — possibly impacting 15 million doses.
